Abiomed (NSDQ:ABMD) today released results from a study of its Impella 2.5 heart pump examining the use of the device in patients with acute myocardial infarction complicated by cardiogenic shock, touting survival benefits associated with the device.
Results from the Danvers, Mass.-based company’s study were published in the Journal of Interventional Cardiology.
Data from the 36-patient retrospective study came from real-world outcomes with the Impella 2.5 during percutaneous coronary interventions on unprotected left main coronary arteries, Abiomed said. The study aimed to analyze whether the initiation of hemodynamic support before PCI would improve survival compared to support post-PCI.
Results indicated that patients treated with the Impella pre-PCI had survival rates of 55% at discharge and 48% at 30-days post discharge, versus 19% and 13% respectively for those treated post-PCI, Abiomed said.
“Patients with cardiogenic shock complicating an acute myocardial infarction due to an unprotected left main coronary artery culprit lesion are some of the sickest and most clinically challenging patients admitted in the cath lab. Our data suggests that early placement of Impella before PCI is vital to survival,” study 1st author Dr. Perwaiz Meraj of Northwell Health said in a press release.
Abiomed said the data supports prior data showing percutaneous heart pumps improved survival in cardiogenic shock patients.
“We commend Dr. Meraj and his coauthors on this application of real-world evidence. We are pleased that this adds to the body of research showing the benefit of placing Impella early and before PCI in the setting of cardiogenic shock,” chief medical officer Dr. Seth Bilazarian said in a prepared statement.
In May, Abiomed said it launched a 3rd generation Impella CP heart pump, touting new features and improved performance with the new model.
